Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

QIAGEN N.V. to Report Fourth Quarter and Full-Year 2014 Results

QGEN

VENLO, The Netherlands, January 16, 2015 /PRNewswire/ --

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans to release its report on results for the fourth quarter and full year 2014 on Wednesday, January 28, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously announced, a conference call is planned for Thursday, January 29, at 15:30 CET / 9:30 ET that will include remarks by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference Call & Webcast Details 

The conference call will begin at 15:30 CET / 9:30 ET on January 29, 2015.

Interested parties may listen to the call by dialing:

+1-855-272-3518 (U.S.), +44-203-059-5869 (UK), +49-69-566-036-000 (Germany)

The webcast will be accessible at http://www.qiagen.com/de/about-us/investors/corporate-calendar

A conference call replay will be available through February 4, 2015, by dialing:

+1-866-268-1947 (U.S.), +44-121-260-4861 (UK), +49-69-710-488-70 (Germany) (passcode: 984749#).

Contact: IR@qiagen.com

About QIAGEN 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts: 

QIAGEN

Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: ir@QIAGEN.com

Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com

SOURCE Qiagen



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today